NASDAQ: WGRXWellgistics Health Inc Stock
$3.10-0.19 (-5.78%)
Updated Apr 21, 2025
WGRX Price
$3.10
Fair Value Price
-$0.26
Market Cap
$161.03M
52 Week Low
$2.32
52 Week High
$5.69
P/E
-20.67x
P/B
23.91x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$18.13M
Earnings
-$6.86M
Gross Margin
9.7%
Operating Margin
-33.23%
Profit Margin
-37.8%
Debt to Equity
7.51
Operating Cash Flow
-$1M
Beta
1.15
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
WGRX Overview
Wellgistics Health, Inc. operates as a wholesaler and distributor of pharmaceutical products to pharmaceutical manufacturers and independent retail pharmacies in the United States. The company distributes generic and branded pharmaceuticals, as well as over-the-counter healthcare and consumer products. It also offers third-party logistics services that include warehousing, inventory management, pick and pack, and shipping to small and mid-size pharmaceutical manufacturers. It also operates DelivMeds platform that serves as a pharmaceutical hub to facilitate the transfer of prescriptions and provide backend clinical concierge services to a network of independent pharmacies; and operates a retail community specialty. The company was formerly known as Danam Health, Inc. and changed its name to Wellgistics Health, Inc. in October 2024. Wellgistics Health, Inc. was incorporated in 2022 and is based in Tampa, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine WGRX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical Retailer
Industry Rating
D
WGRX
Ranked#3 of 4
Ranked#3 of 4
Be the first to know about important WGRX news, forecast changes, insider trades & much more!
WGRX News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how WGRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
WGRX ($3.10) is overvalued by 1,286.16% relative to our estimate of its Fair Value price of -$0.26 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
WGRX ($3.10) is not significantly undervalued (1,286.16%) relative to our estimate of its Fair Value price of -$0.26 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
WGRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more WGRX due diligence checks available for Premium users.
Valuation
WGRX fair value
Fair Value of WGRX stock based on Discounted Cash Flow (DCF)
Price
$3.10
Fair Value
-$0.26
Undervalued by
1,286.16%
WGRX ($3.10) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
WGRX ($3.10) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
WGRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
WGRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-20.67x
Industry
-0.41x
Market
27.14x
WGRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
23.91x
Industry
1.34x
WGRX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
WGRX's financial health
Profit margin
Revenue
$12.4M
Net Income
-$4.3M
Profit Margin
-34.9%
WGRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
WGRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$57.3M
Liabilities
$50.6M
Debt to equity
7.51
WGRX's short-term liabilities ($38.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
WGRX's short-term assets ($15.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
WGRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.7M
Investing
$838.4k
Financing
$2.1M
WGRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
WGRX vs Pharmaceutical Retailer Stocks
Wellgistics Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.